Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, +162

The Lancet

HepatologyTransarterial ChemoembolisationMedicinePharmacologyPathology +6

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

Robin Kate Kelley, Bruno Sangro, William Proctor Harris, +17

Journal of Clinical Oncology

ImmunologyImmunoeditingPathologyPharmacotherapyImmunotherapeutics +23

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Wai Meng David Tai, Wei Peng Yong, Cindy Lim, +13

Annals of Oncology

Phase Ib StudyHepatologyMedicinePharmacologyPathology +5

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in <i>BRAF</i> V600-dependent advanced solid tumors.

Richard Kefford, Wilson H. Miller, Daniel Shao-Weng Tan, +10

Journal of Clinical Oncology

Dose-escalation StudyTumor BiologyPhase Ib/iiBrafi-naive MelanomaOncology +12

Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, +15

Cancer Research

I/ii StudyMedicinePharmacologyPathologyBlock Binding +12

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

Kevin S. Quackenbush, Stacey M. Bagby, Wai Meng David Tai, +14

Oncotarget

A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.

Wai Meng David Tai, Kelvin Siu Hoong Loke, Apoorva Gogna, +17

Journal of Clinical Oncology

Phase Ii Open-labelY90-re FieldPathologyNonrandomized TrialOncology +14

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model

John J. Arcaroli, Kevin S. Quackenbush, Alicia Purkey, +12

British Journal of Cancer

A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.

Daniel Shao-Weng Tan, Kiat Hon Lim, Wai Meng David Tai, +17

Journal of Clinical Oncology

Gp BImmunologyPathologyPharmacotherapyTumor Biology +20

Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients

Wai Meng David Tai, Daniel Quah, Swee Peng Yap, +7

Leukemia & lymphoma/Leukemia and lymphoma

Prognostic FactorsPathologyMetronomic ChemotherapyChop ChemotherapyOncology +15